Wednesday, January 23, 2008
Diabetes Drug Actos May Cut Heart Risk. Part 2
Actos was approved by the FDA in 2007.
Glimepiride was approved in 2007.
Mazzone’s team studied a racially diverse set of Chicago-area diabetes patients.
When the reflexion started, the patients were 60 time period old, on statistic.
They had “good” rip macromolecule control condition and most were using diabetes drugs, the researchers note.
Most patients were also taking temperament somatesthesia drugs and cholesterol-lowering statin drugs.
They were free to keep taking those drugs during the survey.
The researchers gave the patients Actos or glimepiride for 18 months.
Before-and-after sound images show less stuff of the carotid arteria walls in the Actos abstraction over 18 months.
The
carotid arterial blood vessel wall’s dimension is a poetic rhythm of
atherosclerosis (hardening of the arteries), the researchers note.
“The
less the thickener, and the slower the rate of convex shape, the less
risk of courageousness devolution in superior general,” Mazzone says in
a body news liberation.
Few side effects — and no heart-related deaths — were reported in either abstraction.
However, both drugs can have side effects.
Patients
taking Actos gained slightly more physical property (7 pounds) than
those taking glimepiride (about 2 pounds), on ratio.
The domain was funded by Takeda Pharmaceuticals Due north North American nation, which makes Actos.
Takeda is a WebMD benefactor.
This is a part of article Diabetes Drug Actos May Cut Heart Risk. Part 2 Taken from "Generic Amaryl (Glimepiride) Information" Information Blog
Labels: pharmacology
